Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics, Inc

MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric disorders, announced that, in connection with the hiring of Keith J. Sullivan as the company’s President and Chief Executive Officer on July 14, 2020, the company’s Board of Directors authorized the grant to Mr. Sullivan of the following long term equity incentive grants as an inducement material to him accepting employment with the company, each of which was made outside of Neuronetics’ 2018 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) with vesting subject to Mr. Sullivan’s continued employment with the company on the relevant vesting date:

  • 500,000 restricted stock units, 25% of which will vest annually. Each vested restricted stock unit will be settled in one share of the company’s common stock;
  • 500,000 performance restricted stock units (“PRSUs”), which will vest based on appreciation of the company’s common stock price, measured using a trailing 30-day volume-weighted average price of a share of the company’s common stock. Each vested performance restricted stock unit will be settled in one share of the company’s common stock; and
  • 1,000,000 non-qualified stock options, with an exercise price of $1.98, 25% of which will vest on July 14, 2021, and 1/48th of which will vest monthly thereafter.
READ:  USA Technologies Announces $55 Million Common Stock Investment from Multiple Investors

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee